Novel Tumor-Agnostic Agent: 80% RR, but Target Is Rare

The investigational tumor-agnostic drug larotrectinib (LOXO-101, Loxo Oncology) has shown a 75% to 8O% response rate in children and adults with unresectable or metastatic solid tumors that harbor tropomyosin receptor kinase (TRK) fusions.

The latest data on this drug "suggest larotrectinib is likely to be the most effective treatment option for any patient with an advanced solid tumor harboring a TRK fusion," principal investigator David M. Hyman, MD, chief of early drug development at Memorial Sloan Kettering Cancer Center, New York City, told Medscape Medical News.

"Further follow-up will determine the exact duration of this benefit, although it is already in a very clinically meaningful range," he added.

As previously reported by Medscape Medical News, larotrectinib has shown unprecedented high response rates in all 17 unique tumor types in which it has been tested.

More details have now been published in the February 22 issue of the New England Journal of Medicine.

In a pooled analysis of a phase 1/2 clinical trial program conducted in 55 patients (age range, 4 months to 76 years), the response rate was 75% to 80%, as determined on the basis of independent radiologic review and investigator assessment.

A complete response was seen in seven patients (13%), and a partial response in 34 (64%). Stable disease was seen in seven patients (13%).

Source: medscape